NCT03595644

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Trial.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.

Conditions

• Stage IV Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	SBRT+TKI	Received SBRT after three months after EGFR-TKI treatment
DRUG	TKI	Received EGFR-TKI treatment

Timeline

• Start date: 2017-02-12
• Primary completion: 2019-06-10
• Completion: 2020-12-10
• First posted: 2018-07-23
• Last updated: 2021-04-08

Locations

1 site across 1 country: China